Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

•Agonistic antibodies against OX40 are in active clinical development.•Pre-clinical studies suggest sequential therapy is superior to combinational.•We report two cases of ovarian cancer treated with OX40 followed by PD-1/CTLA4 Ab.•Both experienced unusually deep and durable responses.•The cases support further investigation of the relevance of sequential immunotherapy.